Contract analysis

I. Executive Summary The purpose of this memorandum is to provide the engagement team with a comprehensive analysis of the regulatory framework governing qualified cost-sharing arrangements under Treas. Reg. § 1.482-7, in order to inform the defense of PPC's cost-sharing arrangement with PBI in the ongoing IRS Large Business and International ("LB&I") Division examination covering tax years 2017 through 2020 (Exam Te

1. Eligibility requirements for QCSA status — whether PPC and PBI satisfy the requirements for controlled participants under Treas. Reg. § 1.482-7(j)(1), including the substantive involvement standard.

2. PCT payment requirements and valuation methodologies — whether PPC's $312 million PCT payment falls within the arm's-length range, with particular attention to the income method under § 1.482-7(g)(4) and the competing discount rate and revenue projection assumptions.

3. RAB share calculation standards — whether PBI's cost-sharing percentages (38.2% to 42.7%) are consistent with the reasonably anticipated benefits standard under § 1.482-7(e), and whether the IRS's proposed increases are supportable.

4. Cost pool composition and allocation — whether PPC's qualified R&D cost pools for the examination years are properly composed under § 1.482-7(d), including the treatment of stock-based compensation in light of the Altera litigation.

5. Documentation and administrative requirements — whether PPC's contemporaneous documentation satisfies the requirements of § 1.482-7(k) and provides a basis for penalty protection under IRC § 6662(e)(3)(B).

6. Consequences of noncompliance — the potential penalties and adjustments that could result from a finding that PPC's CSA fails to qualify as a QCSA or that PPC's cost-sharing ratios and PCT payment are not arm's-length. Key Conclusion: Based on the analysis set forth below, PPC's CSA satisfies the structural and documentary requirements of Treas. Reg. § 1.482-7, and PPC's cost-sharing ratios and PCT payment are def

II. Factual Background A. The PPC Corporate Structure Penterra Pharmaceuticals Corp. ("PPC") is a Delaware corporation, publicly traded on the Nasdaq Global Select Market under the ticker symbol "PPCA," with its principal executive offices located at 2200 Independence Boulevard, Princeton Junction, New Jersey 08550. PPC is a specialty pharmaceuticals and biotechnology company focused on the development, manufacturing

1. PCT Undervaluation. The IRS has indicated, through its economist Dr. Washburne, that it has independently valued the PCT at approximately $852 million, compared to PPC's $312 million. The IRS's valuation applies the income method with a lower weighted average cost of capital ("WACC") of 7.2% (compared to PPC's 9.8%) and higher revenue growth projections for PBI's non-Americas territories. Although the PCT payment

2. CSA Cost-Sharing Ratio Adjustments. The IRS proposes increasing PBI's cost-sharing percentage by eight to twelve percentage points for each examination year, asserting that PPC's projections of reasonably anticipated benefits understated the non-Americas share of benefits. The proposed adjustments would increase PBI's cost-sharing payments by a total of approximately $235.01 million over the four examination years

3. Economic Substance Challenge. The IRS may assert that key DEMPE functions (Development, Enhancement, Maintenance, Protection, and Exploitation of intangibles) remained in the United States and were performed by PPC personnel, and that PBI lacked sufficient economic substance to justify its claimed share of intangible-related income. This challenge, if successful, could support a recharacterization of the CSA or an

III. Regulatory Framework — Treas. Reg. § 1.482-7 A. Overview and Purpose of the QCSA Regulations Treasury Regulation § 1.482-7 provides the governing regulatory framework for qualified cost-sharing arrangements between controlled participants. Understanding the history, purpose, and structure of these regulations is essential to evaluating the defensibility of PPC's CSA with PBI. Historical Development. The cost-sha

1. Commit to bear a share of IDA costs. Each participant must commit to, and actually bear, its share of the costs of the intangible development activity in proportion to its reasonably anticipated benefits from exploiting the cost-shared intangibles. This commitment must be reflected in the CSA agreement and implemented through actual cost-sharing payments.

2. Reasonably anticipate benefits from exploiting the cost-shared intangibles. Each participant must have a reasonable expectation of deriving economic benefits from the intangibles being developed through the IDA. This requirement ensures that cost-sharing participants are not merely passive funders but rather parties with a genuine commercial interest in the exploitation of the intangibles.

3. Exercise control over the IDA resources and capabilities that it provides. Each participant must exercise substantive control over the resources, capabilities, and rights that it contributes to the IDA. This requirement, which reflects the broader principle of economic substance, ensures that each participant has genuine involvement in the intangible development activity, rather than serving as a mere conduit for

IV. Platform Contribution Transactions ("PCTs") A. Regulatory Requirements for PCTs Treasury Regulation § 1.482-7(g) provides that when a controlled participant makes a "platform contribution" — defined as a contribution of resources, capabilities, or rights that have been developed outside the intangible development activity and that are reasonably anticipated to contribute to the IDA — the other participants must m

2. Revenue growth projections. The IRS's higher revenue projections reflect assumptions about non-Americas market penetration that were not supported by the information available as of the CSA inception date. The regulatory standard requires that projections be "reasonably anticipated" as of the date the CSA was entered into, not based on hindsight. PPC's contemporaneous projections, which were developed by Crestfiel

3. Useful life of contributed intangibles. Differences in the assumed useful life of the contributed intangibles affect the duration of the projected income stream and, consequently, the present value of the PCT. PPC's analysis reflects patent expiration dates and expected generic competition entry, while the IRS's analysis may assume a longer useful life based on different assumptions about brand loyalty, regulatory

V. Reasonably Anticipated Benefits ("RAB") A. Regulatory Standard Treasury Regulation § 1.482-7(e) provides that each controlled participant's share of IDA costs must be proportional to its "reasonably anticipated benefits" from exploiting the cost-shared intangibles. The RAB standard is the cornerstone of the cost-sharing allocation: it ensures that each participant bears a share of the development costs that is com